SAN ANTONIO--(BUSINESS WIRE)--Kinetic Concepts, Inc. (NYSE: KCI) announced today that Ron Silverman, M.D., FACS, has been appointed senior vice president and chief medical officer. Beginning in August, Dr. Silverman will be responsible for KCI’s medical and clinical strategies across the globe as the company continues to expand its product portfolio and enter new markets around the world.

“Ron demonstrates an amazing passion for medical innovation and a deep commitment to making an impact on the lives of patients,” said Cathy Burzik, KCI’s president and CEO. “As KCI introduces new medical technologies in more places around the world than ever, clinical evidence and patient efficacy will remain paramount in all we do. Ron has strong clinical relationships globally and will work with physicians to identify areas of unmet need and to develop innovative research programs that support new product introductions.”

Dr. Silverman has been on staff at the University of Maryland School of Medicine, where he served as chief of the Division of Plastic Surgery and associate professor of Surgery. He has widely recognized clinical expertise in cosmetic and reconstructive surgery, complex wound management, abdominal wall reconstruction and tissue engineering for reconstructive surgery.

For several years, Dr. Silverman has served on KCI’s Scientific Advisory Board, a committee of leading clinical experts that provides medical guidance to the company. He also has been a leading speaker for a number of years at surgeon forums hosted by LifeCell, KCI’s regenerative medicine unit. Dr. Silverman completed his plastic surgery residency at Harvard/Massachusetts General Hospital in Plastic Surgery and earned his medical degree at the University of Maryland School of Medicine. He also is adjunct associate professor of Plastic Surgery at Johns Hopkins School of Medicine.

About KCI

Kinetic Concepts, Inc. (NYSE:KCI) is a leading global medical technology company devoted to the discovery, development, manufacture and marketing of innovative, high-technology therapies and products for the wound care, tissue regeneration and therapeutic support system markets. Headquartered in San Antonio, Texas, KCI's success spans more than three decades and is deeply rooted in a legacy of innovation and a passion for significantly improving the healing and the lives of patients around the world. The Company employs 6,800 people and markets its products in 20 countries. For more information about KCI and how its products are changing the practice of medicine, visit www.KCI1.com. All trademarks designated herein are proprietary to KCI Licensing, Inc. its affiliates and/or licensors.